EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired …
2021年6月1日 · Along with driver mutations, EGFR drives metastasis in many ways. Paracrine loops comprising tumor and stromal cells enable EGFR to fuel invasion across tissue barriers, survival of clusters of circulating tumor cells, as well as colonization of distant organs.
EGFR Lung Cancer: Symptoms, Diagnosis, Treatment, Outlook - Healthline
2023年1月5日 · Errors in the EGFR gene cause abnormal cell growth and division. Learn about EGFR mutation lung cancer, and discover how the mutation affects treatment.
EGFR and Lung Cancer - American Lung Association
2024年9月26日 · EGFR-positive lung cancer represents about 10-15% of lung cancers in the United States and most often appears in the adenocarcinoma subtype of non-small cell lung cancer. In Asian populations, the incidence of EGFR mutations is substantially higher.
EGFR Mutation and Lung Cancer: What is it and how is it treated?
The FDA first approved gefitinib in 2003 for patients with advanced NSCLC whose tumors express the epidermal growth factor receptor (EGFR) mutation. This targeted therapy works by inhibiting the EGFR pathway, which is often overactive in certain types of lung cancer, leading to reduced tumor growth.
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
2021年6月1日 · Paracrine loops comprising tumor and stromal cells enable EGFR to fuel invasion across tissue barriers, survival of clusters of circulating tumor cells, as well as colonization of distant organs. We conclude by listing all clinically approved anti-cancer drugs targeting either EGFR or HER2.
Epidermal growth factor receptor (EGFR) in lung cancer: an …
2010年2月4日 · Two oral anti-cancer drugs that inhibit EGFR, gefitinib (Iressa) and erlotinib (Tarceva), have recently been approved for use in advanced non-small cell lung cancer, and mutations in EGFR have been discovered in association with some lung cancers.
New EGFR-targeting Combination Therapy for Lung Cancer
The FDA approved lazertinib plus amivantamab-vmjw for the treatment of certain EGFR-mutated lung cancers. The U.S. Food and Drug Administration (FDA) has approved lazertinib (Lazcluze), in combination with amivantamab-vmjw (Rybrevant), for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC ...
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired …
2021年6月1日 · Along with driver mutations, EGFR drives metastasis in many ways. Paracrine loops comprising tumor and stromal cells enable EGFR to fuel invasion across tissue barriers, survival of clusters of circulating tumor cells, as well as colonization of distant organs.
Overcoming therapy resistance in EGFR -mutant lung cancer - Nature
2021年4月15日 · Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR)-activating...
Circumventing the roadblocks to targeting EGFR-driven cancers
2022年4月28日 · Alterations in epidermal growth factor receptor (EGFR) are detected in 2.8% of all cancers, which makes this receptor tyrosine kinase one of the more common oncogenic drivers,...